February 8th, 2025, Shanghai, China—3D Medicines Inc. (1244.HK) today announced the appointment of Mr. Gan Ding as Chief Commercial Officer (CCO). With three decades of experience in the biopharmaceutical industry across China, the United States, and internationally, Mr. Ding brings a wealth of expertise that will drive the future commercial development of 3D Medicines.

With the widespread clinical application of the subcutaneous injection of PD-L1 antibody drug 恩维达® (Envafolimab)in tumor treatment, good news of i...

VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER

(Hong Kong, December 15 , 2022) A biopharmaceutical company in China for the development and commercialization of next-generation tumor immunotherapy drugs - 3D Medicines Inc. (“ 3D Medicines” or the “Company”, Stock Code: 1244.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange”) today. 

Beijing, China October 8, 2022- 3D Medicines Inc. announced today that the subject has been dosed in the Phase I clinical trial for 3D189 (also known as galinpepimut-S, or GPS), which is the first clinical trial in China for this product to assess the safety and immunogenicity of 3D189 in patients with hematological malignancies. The first dosing of the first participant was completed. 3D Medicines holds the exclusive license from SELLAS to develop, manufacture and commercialize 3D189 in China, Hong Kong, Macau and Taiwan region for all therapeutic and other diagnostic uses.

Beijing, China April 18, 2022 - 3D Medicines Inc. (3D Medicines) announces that the multi-center, open-label phase Ib/II clinical trial of Batiraxcept (3D229) in combination with envafolimab or lenvatinib in patients with advanced solid tumor was approved by China’s National Medical Products Administration (NMPA).